Model Name
Pseudomonas aeruginosa (ATCC 27853), Peritonitis, LD90-100

Item Number
608620

Introduction
This model assesses the efficacy of test articles at protecting against a lethal peritonitis infection. The procedure can be used to evaluate small molecules, vaccines and biologics. P. aeruginosa strain ATCC 27853 is the CLSI reference standard for in vitro susceptibility testing of antimicrobial agents. It is virulent in mice and commonly employed for in vivo efficacy analysis.

Procedure Summary
Groups of 10 immune competent mice are used. Each animal is inoculated with an intraperitoneally administered LD90-100 dose of pathogen with 5% mucin. Test substance and vehicle are administered one hour later. Doses may be administered IV, SC, PO, IM, IP or by IV infusion. Mortality is recorded daily during the following 7 days. Prevention of mortality in 50 percent or more (>50%) of the animals indicates significant activity. The Minimum Effective Dose (MED) is defined as the dose that results in survival of 50% (or more) of the test animals.

Turnaround Time(s)
6 weeks from sample receipt

Literature

Optional Services
Cytokine analysis, with Luminex, can be performed upon request.

Related Assay(s) (Item # - Assay Name - Species)
614030* - Pseudomonas aeruginosa (ATCC 27853) MIC - Bacteria
608650 - Pseudomonas aeruginosa (ATCC 27853), Thigh Infection Model, CFU/g - Mouse
608640 - Pseudomonas aeruginosa (ATCC 27853), Lung Infection Model, CFU/g - Mouse
608660 - Pseudomonas aeruginosa (ATCC 27853), Thigh Infection Model, Rat, CFU/g - Rat
*provided by partner lab Eurofins Pharma Discovery Services

Modified Protocols
We will readily accommodate client-specified alterations.

Laboratory
These assays are performed at our AAALAC accredited BSL2 laboratory in Taipei, Taiwan.

Animal Welfare
All aspects of this work is performed in general accordance with the Guide for the Care and Use of laboratory animals (National Academy Press, Washington, DC, 2011). The study protocol was approved by the Pharmacology Discovery Services IACUC and is performed with the oversight of veterinarians to assure the humane treatment of laboratory animals.

Reference Compound(s)
Gentamicin, Imipenem

For current details about our Company address and contact information, please reference our website
http://www.pharmacologydiscoveryservices.com/company-info/
Graph(s)

608620 *Pseudomonas aeruginosa* (ATCC 27853) Peritonitis

**LD	extsubscript{90-100}**

**Gentamicin (GEN) efficacy**

![Graph showing Gentamicin (GEN) efficacy](image)

**Days after infection**

608620 *Pseudomonas aeruginosa* (ATCC 27853) Peritonitis

**LD	extsubscript{90-100}**

**Imipenem (IPM) efficacy**

![Graph showing Imipenem (IPM) efficacy](image)

**Days after infection**

Last modified November 20, 2017